Allogene Therapeutics, Inc. (ALLO)

2,9200 +0,1600 (+5,80 %) À la clôture : 04:00PM EDT

Allogene Therapeutics, Inc.

210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700
https://www.allogene.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 232

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Arie S. Belldegrun F.A.C.S., M.D.	Co-Founder & Executive Chairman	649,1k	S.O.	1949
Dr. David D. Chang M.D., Ph.D.	Co-Founder, President, CEO & Director	994,6k	S.O.	1960
Mr. Joshua A. Kazam	Co-Founder & Director	260,5k	S.O.	1977
Mr. Timothy L. Moore Ph.D.	Executive VP & Chief Technical Officer	554,35k	S.O.	1961
Dr. Zachary J. Roberts M.D., Ph.D.	Executive VP of Research & Development and Chief Medical Officer	747,39k	S.O.	1978
Mr. Geoffrey M. Parker	Executive VP & CFO	S.O.	S.O.	1965
Mr. Earl M. Douglas Esq.	Senior VP, General Counsel, Compliance Officer & Corporate Secretary	S.O.	S.O.	1963
Ms. Susan R. Lundeen	Chief People Officer	S.O.	S.O.	1966
Ms. Christine Cassiano	Executive VP, Chief Corporate Affairs & Brand Strategy Officer	S.O.	S.O.	S.O.
Yinlin Chen	Senior Vice President of Finance	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Allogene Therapeutics, Inc. en date du 29 avril 2024 est 9. Les scores principaux sont Audit : 2; Société : 9; Droits des actionnaires : 8; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.